Pharmacokinetic-Pharmacodynamic (PK-PD) Model for Tolvaptan in Patients with Hypervolemic Hyponatremia

被引：0
|
作者：
Van Wart, Scott [1 ]
Shoaf, Susan [2 ]
Mallikaarjun, Suresh [2 ]
Mager, Donald [1 ]
机构：
[1] SUNY Buffalo, Buffalo, NY 14260 USA
[2] Otsuka, Rockville, MD USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2015年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
W-06
引用
收藏
页码：S76 / S76
页数：1
相关论文
共 50 条
  • [1] A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip
    Sung, Jong Hwan
    Kam, Carrie
    Shuler, Michael L.
    LAB ON A CHIP, 2010, 10 (04) : 446 - 455
  • [2] HYDROMORPHONE BIOAVAILABILITY AND PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) RELATIONSHIPS
    INTURRISI, C
    PORTENOY, R
    STILLMAN, M
    COLBURN, W
    FOLEY, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (02) : 162 - 162
  • [3] METHADONE INFUSIONS - PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) RELATIONSHIPS
    INTURRISI, C
    PORTENOY, R
    MAX, M
    COLBURN, W
    FOLEY, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 41 (02) : 211 - 211
  • [4] Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling of Tolvaptan and Diuretic Use on Fluid and Electrolyte Balance in Healthy Subjects
    Van Wart, Scott
    Shoaf, Susan
    Mallikaarjun, Suresh
    Mager, Donald
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 : S43 - S44
  • [5] PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) MODELING OF MIDAZOLAM-FLUMAZENIL INTERACTIONS
    FISET, P
    EGAN, T
    LEMMENS, H
    SHAFER, S
    STANSKI, D
    ANESTHESIOLOGY, 1993, 79 (3A) : A362 - A362
  • [6] How pharmacokinetic-pharmacodynamic (PK-PD) parameters influence antibiotic use
    Mazzei, T.
    JOURNAL OF CHEMOTHERAPY, 2006, 18 : 19 - 21
  • [7] A Combined Pharmacokinetic-Pharmacodynamic (PK-PD) Model for Tumor Growth in the Rat with UFT Administration
    Sung, Jong Hwan
    Dhiman, Anjali
    Shuler, Michael L.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 98 (05) : 1885 - 1904
  • [8] PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) MODELING FOR METFORMIN IN HEALTHY VOLUNTEERS.
    Kim, Y.
    Cho, S.
    Lee, D.
    Son, H.
    Roh, H.
    Son, M.
    Heo, Y.
    Park, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S48 - S48
  • [9] Pharmacokinetic/pharmacodynamic (PK/PD) model for tolvaptan (TOL) in patients with congestive heart failure (CHF) and/or hyponatremia (HYP)
    Van Wart, SA
    Cirincione, BB
    Ludwig, EA
    Chen, X
    Shoaf, S
    Grasela, TH
    Mallikaarjun, S
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P1 - P1
  • [10] PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) NONPARAMETRIC EVALUATION OF NAPROXEN (NAP) IN DENTAL PAIN
    YOUNG, D
    PAL, B
    DEVANE, J
    FOSSLER, M
    GASTON, G
    COOPER, S
    BUTLER, J
    BURKE, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (02) : 145 - 145
12345